- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
Novavax has submitted a formal request to the US Food and Drug Administration (FDA) for its COVID-19 vaccine. In a press release, the manufacturer noted they have completed at least two Phase 3 clinical trials. The studies found the vaccine was effective, and had few serious or severe adverse effects. The most common side effects were headache, nausea or vomiting, muscle and join pain, fatigue, and pain at the injection site. If approved by the FDA, Novavax would be the fourth vaccine to be made available in the US.
Further information on Novavax is available here.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
